We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




SuppreMol and Protagen to Identify SLE Therapy-Related Biomarkers

By LabMedica International staff writers
Posted on 10 Aug 2011
SuppreMol GmbH (Munich, Germany), a privately held biopharmaceutic company, and Protagen AG (Dortmund, Germany) a specialist in in-vitro diagnostics (IVD) and good manufacturing practice (GMP)-compliant protein analysis, will collaborate to identify therapy-related biomarkers in patients with Systemic Lupus Erythematosus (SLE). More...


Using Protagen's UNIarray approach, specific interactions of autoantibodies from patients with autoantigens can be detected rapidly and efficiently. This enables a broad, highly specific search for novel blood based biomarkers. The basis of this technology is founded in the production of recombinant human proteins derived from tissue specific human expression libraries and spotted onto filter membranes.

The Protagen biomarker portfolio will be used by SuppreMol to identify autoantibodies in the serum of SLE patients. Patients will be identified who are most likely to benefit from SuppreMol's product SM101, a recombinant, soluble, nonglycosylated version of the Fc receptor IIb.

The protein SM101 binds to autoantibody/autoantigen complexes and blocks the triggering of Fc receptors on the surface of immune cells. The immune response is downregulated and activation of the inflammation cascade typically seen in autoimmune diseases is prevented.

Peter Buckel, CEO of SuppreMol explained, "Our findings may [also] allow the classification of patients into subgroups as SLE is a disease with very diverse manifestations. The UNIarray technology platform of Protagen offers a unique opportunity to explore the potential for a personalized SLE therapy concomitant to the clinical development of SM101."

SuppreMol develops therapeutics for the treatment of autoimmune diseases and allergies. The company is developing soluble Fc gamma receptors (sFcRs), which are recombinant autologous therapeutic proteins with a strong immunosuppressive potential. The company plans to develop sFcRs for the treatment of Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and other autoimmune conditions.

Related Links:
SuppreMol GmbH
Protagen AG



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.